Use your browser's back button to choose another title or click here for a New Search.

How to Get the Poster

 Open poster (pdf)




Bookmark and Share





Body Mass Index (BMI) and Obesity Prevalence Among Substance Abuse Participants from NIDA's Clinical Trials Network (CTN).

Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, San Diego, CA, June 15-20, 2013.

Abigail G. Matthews, PhD (EMMES Corporation), Lian Hu, PhD, MPH (EMMES Corporation), Li Lu, MS (EMMES Corporation), Paul C. VanVeldhuisen, PhD (EMMES Corporation), Betty Tai, PhD (NIDA Center for the Clinical Trials Network), Nora D. Volkow, MD (NIDA).

Though behavioral and pathological similarities between binge eating disorder and substance use disorders are known to researchers, associations between them are poorly studied. We compared pre-treatment BMI in substance users from 7 National Drug Abuse Treatment Clinical Trials Network (CTN) clinical trials with BMIs for age, race and gender comparable participants from the National Health and Nutrition Examination Survey (NHANES). Standardized Prevalence Ratio (SPR) of obesity (BMI>=30kg/m2) was estimated and adjusted for age, gender, and race. ANOVA test was used to compare adjusted mean BMI. Cigarette smoking status was also adjusted for in a subset of participants with available data. Results: CTN participants had lower BMI (N=2017, mean=26.6kg/m2) than NHANES participants (N=10966, mean=28.6kg/m2, p<0.0001). Crude obesity prevalence was 23% and 37% in CTN and NHANES participants, respectively. Adjusted obesity prevalence in CTN participants was 32% lower than NHANES (SPR=0.68, 95% CI: 0.62-0.74). Obesity prevalence in NHANES participants was 2.75 times that in CTN opiate users (N=908, SPR=2.75, 95% CI: 2.27-3.38), but only 1.21 times that in CTN stimulant users (N=1109, SPR=1.21, 95% CI: 1.09-1.34). After further adjusting for smoking, obesity prevalence in CTN stimulant users was not different from NHANES participants (SPR=0.99, 95% CI: 0.90-1.10). BMI for CTN opiate users (mean=25.1kg/m2) was lower than for stimulant users (mean=28.2kg/m2, p<0.001), while obesity prevalence in stimulant users was 2.54 times that in opiate users (SPR=2.54, 95% CI: 2.29-2.81).

Conclusions: Obesity prevalence was significantly lower in substance abusers from CTN trials than in a matched sample of general population. The difference was driven by significantly lower BMI and obesity prevalence in opiate than stimulant users, suggesting substance-specific effects on energy homeostasis and weight regulation. These results warrant further research on relationships between substance use, diet and weight. (Poster, PDF, English, 2013)

Keywords: Body Mass Index (BMI) | CTN platform/ancillary study | Eating disorders | Heroin | Prescription-type opiates | Smoking | Stimulant abuse | College on Problems of Drug Dependence (CPDD) annual meeting, 2013

Document No: 997

Submitted by Janet Van Dyke, EMMES, 6/20/2013.


Hu, Lian search mail
Lu, Li search mail
Matthews, Abigail G. search mail
Tai, Betty search
VanVeldhuisen, Paul C. search mail
Volkow, Nora D. search

dark blue line
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 6/2013 --
dark blue line